The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options.

Autor:	von Arx C; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Calderaio C; Clinical and Translational Oncology, Scuola Superiore Meridionale (SSM), Naples, Italy.; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Calabrese A; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Marciano B; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Martinelli C; Clinical and Translational Oncology, Scuola Superiore Meridionale (SSM), Naples, Italy.; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Di Lauro V; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Cerillo I; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Cianniello D; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., De Laurentiis M; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.; Clinical and Translational Oncology, Scuola Superiore Meridionale (SSM), Naples, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Dec 19; Vol. 14, pp. 1447508. Date of Electronic Publication: 2024 Dec 19 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1447508
Abstrakt:	The advent and success of new drugs for treating HER2-positive metastatic breast cancer has led to a constant improvement in disease and progression-free survival as well as overall survival. Despite these advantages, the overall survival and quality of life of patients with HER2-positive breast cancer brain metastases are significantly worse than the ones of patients with HER2-positive breast cancer metastases outside the brain. For this reason, prevention and treatment of brain metastasis remain a major clinical challenge and the keys to further improving the clinical and survival outcomes of HER2-positive breast cancer patients. This review discusses the etiopathogenesis of brain metastasis, the currently available treatments, and the future perspective on new treatment strategies and diagnostic tools. Competing Interests: CvA: honoraria or travel grants from Daiichi Sankyo, Gilead, Ipsen, Takeda, Sanofi and AstraZeneca. VDL: honoraria or travel grants from Amgen, Seagen, Veracyte, Pfizer, Roche, Genetic and Exact Sciences. MDL: honoraria or speaker’s fee from AstraZeneca, Daiichi Sankyo, Exact Sciences, Eisai Eli Lilly, Gilead, Genetic, GSK, Genzyme, MSD, Menarini, Novartis, Pfizer, Pierre Fabre, Seagen, Tomalab, Sanofi, Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 von Arx, Calderaio, Calabrese, Marciano, Martinelli, Di Lauro, Cerillo, Cianniello and De Laurentiis.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu